INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
| Market Capitalization | $60.7323 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.213 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.22 |
| EBITDA | -7,575.509 |
| Profit Margin | 0 |
| Operating Margin TTM | -4.7085 |
| Return on Assets TTM | -0.2144 |
| Return on Equity TTM | -0.3744 |
| Revenue TTM | 1,904.923 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2017-06-30 | 4.2 | |||
| 2018-06-30 | 7.21 | |||
| 2019-06-30 | 8.73 | 2,302.24 | ||
| 2020-06-30 | 98.39 | 2,895.049 | ||
| 2021-06-30 | 468.096 | 64.045 | 404.051 | 7,444.259 |
| 2022-06-30 | 276.745 | 56.446 | 220.299 | 9,439.517 |
| 2023-06-30 | 751.91 | 44.48 | 707.43 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2017-06-30 | 650.05 | 726.9 | 468.96 | 0 | 6,645.5 | |
| 2018-06-30 | 1,445.66 | 1,453.14 | 322.65 | 0 | 9,298.39 | |
| 2019-06-30 | 7,556.661 | 7,626.534 | 491.855 | 0 | 16,980.108 | |
| 2020-06-30 | 7,326.861 | 7,374.236 | 899.122 | 0 | 19,286.885 | |
| 2021-06-30 | 4,998.564 | 33,521.7 | 4,464.97 | 346.634 | 51,832.009 | |
| 2022-06-30 | 15,394.847 | 30,779.459 | 2,486.622 | 357.032 | 69,053.379 | |
| 2023-06-30 | 7,812.511 | 21,508.82 | 1,893.42 | 0 | 69,053.38 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2017-06-30 | -2,378.31 | -2,447.7 | 0 | |||
| 2018-06-30 | -1,965.27 | 795.61 | 1,445.657 | |||
| 2019-06-30 | -1,717.273 | -1,570.72 | 6,111.004 | 1,445.657 | 7,556.661 | |
| 2020-06-30 | -3,253.553 | -2,536.58 | -229.8 | 7,556.661 | 7,326.861 | |
| 2021-06-30 | -12,367.119 | -5,260.38 | -2,328.297 | 7,326.861 | 4,998.564 | |
| 2022-06-30 | -18,195.977 | -6,061.16 | 10,396.283 | 4,998.564 | 15,394.847 | |
| 2023-06-30 | -8,969.241 | -7,024.57 | -7,582.34 | 15,394.847 | 7,812.511 |